Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Dasatinib × Plasma cell × Clear all

Phase

Status

Terminated 5 Recruiting 2 Withdrawn 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2 Plasma cell 1 Myeloid 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 18 daratumumab 15 Cyclophosphamide 9 Calcium Dobesilate 7 Bortezomib 7 pomalidomide 6 carfilzomib 6 Lenalidomide 6 fludarabine 4 belantamab mafodotin 4 talquetamab 3 dexamethasone acetate 3 dexamethasone 21-phosphate 3 auricularum 3 Specimen Handling 3 Biopsy 3 isatuximab 2 Maintenance 2 Hyaluronoglucosaminidase 2 Exercise Therapy 2 Drug Therapy 2 CT103A chimeric antigen receptor 2 zanubrutinib 1 trametinib 1 selinexor 1 pembrolizumab 1 ixazomib 1 ibrutinib 1 iberdomide 1 fludarabine phosphate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05944783 2025-02-12

BE-Dasatinib

Centro de Atencion e Investigacion Medica

Phase 4 Not yet recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡